Rheumatology International

, Volume 32, Issue 3, pp 601–606

Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 in patients with systemic lupus erythematosus

  • Maryam Sahebari
  • Zahra Rezaieyazdi
  • Mohammadreza J. Nakhjavani
  • Mohammadreza Hatef
  • Mahmoud Mahmoudi
  • Saaid Akhlaghi
Original Article


Recent researches suggest that imbalance in apoptotic process may lead to susceptibility to systemic lupus erythematosus (SLE). Production of pro-inflammatory cytokines, such as IL-18, has important role in autoimmune process in lupus. There are cumulative data on the pro-apoptotic role of IL-18, in the Fas-mediated apoptosis. Soluble Fas (Apo/1-CD95) is a marker of apoptosis that appears to increase in serum of SLE patients. Previous studies demonstrated increasing serum concentrations of soluble Fas (sFas) and IL-18 in SLE. To assess the correlation between serum concentrations of sFas and IL-18 in SLE patients, 114 SLE patients were selected randomly at the different stages of disease activity according to SLEDAI2K. IL-18 and sFas serum concentrations were compared in patients and fifty randomly selected healthy volunteers. The correlations of IL-18 and sFas serum concentrations with SLEDAI2K and with each other were evaluated in patients. There were a significant difference between serum concentrations of sFas and IL-18 in the case and control groups (P = 0.001). There was a significant correlation between serum concentrations of sFAS and IL-18 in SLE patients (P < 0.0001, r = 0.411). The elevations of IL-18 and sFas(Apo/1-CD95) serum concentrations in SLE patients are significantly correlated.


Soluble Fas (CD95/Apo-1) Interleukine-18(IL-18) Systemic lupus erythematosus Apoptosis 


  1. 1.
    Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J (2008) Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 17:371–375PubMedCrossRefGoogle Scholar
  2. 2.
    Sahin M, Aydıntug O, Tunc SE, Tutkak H, Nazıroğlu M (2007) Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem 40:6–10PubMedCrossRefGoogle Scholar
  3. 3.
    Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126–1129PubMedCrossRefGoogle Scholar
  4. 4.
    Hao JH, Ye DQ, Zhang GQ, Liu HH, Dai H, Huang F, Pan FM, Su H, Dong MX, Chen H, Wang Q, Zhang XJ (2006) Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese. Arch Dermatol Res 297(7):329–332PubMedCrossRefGoogle Scholar
  5. 5.
    Alecu M, Coman G, Alecu S (2000–2001) Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus. Rom J Intern Med 38–39:83–88Google Scholar
  6. 6.
    Courteny PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL (1999) Lymphocyte apoptosis in systemic lupus erythematosus, relationship with Fas expression, serum soluble FAS and diease activity. Lupus 8:508–513CrossRefGoogle Scholar
  7. 7.
    Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F (2003) Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus 12:8–14PubMedCrossRefGoogle Scholar
  8. 8.
    Carroll HP, Paunovic V, Gadina M (2008) Crossed signals: the role of interlukin-15 and -18 in autoimmunity. Rheumatology 47:1269–1277PubMedCrossRefGoogle Scholar
  9. 9.
    Boraschi D, Dinarello CA (2006) IL-18 in autoimmunity: review. Eur Cytokine Netw 17(4):224–252PubMedGoogle Scholar
  10. 10.
    Calvani N, Richards HB, Tucci M, Pannarale G, Silvester F (2004) Upregulation of IL-18 and predominance of Th1 immune response is a hallmark of lupus nephritis. Clin Xp Immunol 138:171–178CrossRefGoogle Scholar
  11. 11.
    Park MC, Park YB, Lee SK (2004) Elevated interlukin- 18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 23:225–229PubMedCrossRefGoogle Scholar
  12. 12.
    Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M (1997) Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17:3253–3258PubMedGoogle Scholar
  13. 13.
    Kitaura H, Tatamiya M, Nagata N, Fujimura Y, Eguchi T, Yoshida N, Nakayama K (2006) IL-18 induces apoptosis of adherent bone marrow cells in TNF- α mediated osteoclast formation in synergy with IL-12. Immunol Lett 107:22–31PubMedCrossRefGoogle Scholar
  14. 14.
    Reddy P (2004) Interleukin-18: recent advances. Curr Opin Hematol 11:405–410PubMedCrossRefGoogle Scholar
  15. 15.
    Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H (1996) Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173:230–235PubMedCrossRefGoogle Scholar
  16. 16.
    Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JN (2007) Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset still’s disease. Arthritis Rheum (Arthritis Care Res) 57:1530–1538CrossRefGoogle Scholar
  17. 17.
    Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA (2006) Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat. 13:230–234PubMedCrossRefGoogle Scholar
  18. 18.
    Nakae H, Zheng YJ, Wada H, Tajimi K, Endo S (2003) Involvement of IL-18 and soluble fas in patients with postoperative hepatic failure. Eur Surg Res 35:61–66PubMedCrossRefGoogle Scholar
  19. 19.
    El-Masry S, Lotfy M, Nasif WA, El-Kady IM, Al-Badrawy M (2007) Elevated serum level of interleukin (IL)-18, interferon (IFN)-gamma and soluble Fas in patients with pulmonary complications in tuberculosis. Acta Microbiol Immunol Hung 54:65–77PubMedCrossRefGoogle Scholar
  20. 20.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRefGoogle Scholar
  21. 21.
    Dalboni MA, Sardenberg C, Andreoli MC, Watanabe R, Canziani ME, Santos BF, Liangos O, Jaber BL, Draibe S, Cendoroglo M (2003) Soluble FAS a novel marker of inflammation in uremia. Artif Organs 27:678–691CrossRefGoogle Scholar
  22. 22.
    Sahebari M, hatef, Rezaiyeyazdi Z, Abbasi M, Abbasi B, Mahmoudi M (2010) Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in khorasan. Iran. Arch Iran Med 13:135–142Google Scholar
  23. 23.
    Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C (2009) Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment. Int Immunol. doi:10.1093/intimm/dxn142 PubMedGoogle Scholar
  24. 24.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H (1999) Differential anti tumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163:583–589PubMedGoogle Scholar
  25. 25.
    Satoko I, Nobuhiro S, Yoshihiro I, Shigeatsu E (2005) A study of interleukin 18 and sFas in septic multiple organ dysfunction syndrome. J Iwate Med A 5:497–503Google Scholar
  26. 26.
    Mariño E, Cardier JE (2003) Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-a and Fas (CD95). Cytokine 22:142–148PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Maryam Sahebari
    • 1
  • Zahra Rezaieyazdi
    • 1
  • Mohammadreza J. Nakhjavani
    • 2
  • Mohammadreza Hatef
    • 1
  • Mahmoud Mahmoudi
    • 3
  • Saaid Akhlaghi
    • 1
  1. 1.Rheumatic Diseases Research Center, Ghaem Hospital, Faculty of MedicineMashhad University of Medical SciencesMashhadIran
  2. 2.Tabriz University of Medical SciencesTabrizIran
  3. 3.Immunology Research Center, Faculty of MedicineMashhad University of Medical SciencesMashhadIran

Personalised recommendations